NEW YORK, Feb. 10 (GenomeWeb News) - Carlsbad, Calif.-based Invitrogen yesterday announced the closing of its acquisition of BioReliance in an all-cash deal conducted through its subsidiary entity, Baseball Acquisition.
BioReliance, a Rockville, Md.-based contract service organization, will operate as a wholly-owned subsidiary of Invitrogen. The firm in January announced that it would close a 44-employee Worchester, Mass., facility it acquired with a merger with Q-One Biotech in September.
BioReliance shares were delisted from the Nasdaq exchange, and ceased trading at the close of business on Friday, Feb. 6.
Invitrogen announced in December that it would acquire BioReliance for $500 million. Invitrogen paid $48 per share for BioReliance's approximately 8.4 million shares, valuing today's transaction at $403,200,000.